Radhika Guleri Bhardwaj

Radhika Guleri Bhardwaj

Auto-generated profile, based on publicly available information

Radhika Guleri Bhardwaj

School of Arts & Science, American International University

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
KOKhaled Orabi
Khaled Orabi
MAMohamed Salah Abaza
Mohamed Salah Abaza
Khalid El SayedKhalid El Sayed
Khalid El Sayed
AEAhmed Y Elnagar
Ahmed Y Elnagar
RARaja'a Al-Attiyah
Raja'a Al-Attiyah
RGRadhika P Guleri
Radhika P Guleri
It has been shown that proteasome inhibition leads to growth arrest in the G1 phase of the cell cycle and/or induction of apoptosis. However, it was found that some of these inhibitors do not induce apoptosis in several human normal cell lines. This selective activity makes proteasome inhibition a promising target for new generation of anticancer drugs. Clinical validation of the proteasome, as a therapeutic target in oncology, has been provided by the dipeptide boronic acid derivative; bortezomib. Bortezomib has proven to be effective as a single agent in multiple myeloma and some forms of non-Hodgkin’s lymphoma. Syringic acid (4-hydroxy-3,5-dimethoxybenzoic acid, 1), a known phenolic acid, was isolated from the methanol extract of Tamarix aucheriana and was shown to possess proteasome inhibitory activity.

1 October 2016 in BMC Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
MAMohamed Salah Abaza
Mohamed Salah Abaza
MAMohammad Afzal
Mohammad Afzal
RARaja’a J. Al-Attiyah
Raja’a J. Al-Attiyah
RGRadhika Guleri
Radhika Guleri
Natural products are valuable sources for anticancer agents. In the present study, methylferulate (MF) was identified for the first time from Tamarix aucheriana. Spectral data were used for identification of MF. The potential of MF to control cell growth, cell cycle, apoptosis, generation of reactive oxygen species (ROS), cancer cell invasion, nuclear factor kappa B (NFkB) DNA-binding activity and proteasomal activities, as well as the enhancement of chemosensitivity in human colorectal cancer cells, were evaluated. The possible molecular mechanism of MF’s therapeutic efficacy was also assessed. Column chromatography and spectral data were used for isolation and identification of MF. MTT, immunofluorescence, flow cytometry, in vitro invasion, fluoremetry, EIA and Real time qPCR were used to measure antiproliferative, chemo-sensitizing effects and other biochemical parameters. MF showed a dose-dependent anti-proliferative effect on colorectal cancer cells (IC50 = 1.73 – 1.9 mM) with a nonsignificant cytotoxicity toward normal human fibroblast. Colony formation inhibition (P ≤ 0.001, 0.0001) confirmed the growth inhibition by MF. MF arrested cell cycle progression in the S and G2/M phases; induced apoptosis and ROS generation; and inhibited NF-kB DNA-binding activity, proteasomal activities and cell invasion in colorectal cancer cells. MF up-regulated cyclin-dependent kinase inhibitors (p19 INK4D, p21WAF1/CIP1, p27KIP1), pro-apoptotic gene expression (Bax, Bad, Apaf1, Bid, Bim, Smac) and caspases (caspase 2, 3, 6, 7, 8, 9). Moreover, MF down-regulated cyclin-dependent kinases (Cdk1, Cdk2) and anti-apoptotic gene expression (c-IAP-1, c-IAP-2, Bcl2,FLIP). In addition, MF differentially potentiated the sensitivity of colorectal cancer cells to standard chemotherapeutic drugs. MF showed a multifaceted anti-proliferative and chemosensitizing effects. These results suggest the chemotherapeutic and co-adjuvant potential of MF.

27 August 2025 in Journal of Oral Microbiology
Verified
Journal Article
Open access
MKMaribasappa Karched
Maribasappa Karched
RBRadhika Guleri Bhardwaj
Radhika Guleri Bhardwaj
MAManal Abu Al-Melh
Manal Abu Al-Melh
MQM.A. Qudeimat
M.A. Qudeimat
Low-abundance bacterial (LAB) species, despite their low prevalence, may contribute to oral inflammatory diseases by triggering host immune responses. The NLRP3 inflammasome plays a key role in inflammation, but its activation by LAB species remains unclear. This study examined whether selected LAB species and their biofilm-secreted components induce cytokine production and inflammasome activation in human peripheral blood mononuclear cells (PBMCs). Biofilms of selected LAB species were established, and supernatants were collected. PBMCs were stimulated with biofilms or supernatants, and cytokine levels were quantified using ELISA. The expression of NLRP3 and Caspase-1 genes was analyzed through real-time PCR. Biofilms induced significantly higher levels of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β, and IL-18) compared to supernatants, with C. hominis, N. flavescens, and D. pneumosintes being the most potent inducers. Biofilms also led to a marked increase in NLRP3 expression, while supernatants primarily activated Caspase-1 expression, indicating distinct inflammasome activation pathways. These findings highlight the immunostimulatory potential of LAB species, particularly their ability to activate NLRP3 and drive inflammation. The differential activation of NLRP3/Caspase-1 by biofilms and supernatants suggests distinct pathogenic mechanisms. Targeting such mechanisms/pathways could offer new therapeutic strategies to mitigate inflammation linked to oral infections.

14 August 2025 in Journal of Oral Pathology & Medicine
Verified
Journal Article
Closed access
MKMaribasappa Karched
Maribasappa Karched
AHAsma Hanif
Asma Hanif
RBRadhika G. Bhardwaj
Radhika G. Bhardwaj
MKMAI E Khalaf
MAI E Khalaf
MQM.A. Qudeimat
M.A. Qudeimat